More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$42.69B
EPS
0.15
P/E ratio
22.4
Price to sales
2.9
Dividend yield
1.23%
Beta
0.196564
Previous close
$9.59
Today's open
$9.53
Day's range
$9.51 - $9.60
52 week range
$8.71 - $11.42
show more
CEO
Brian McNamara
Employees
24000
Headquarters
Weybridge,
Exchange
New York Stock Exchange
Shares outstanding
4.45B
Issue type
American Depository Receipt
Healthcare
Pharmaceuticals
Haleon Recognized by Fast Company as a 2025 Brands That Matter Honoree
WARREN, N.J.--(BUSINESS WIRE)--Haleon, a global leader in consumer health, today announced it has been honored in Fast Company's 2025 Brands That Matter list in the Family of Brands category, which highlights companies that created cultural moments for multiple brands across their portfolios. The annual list recognizes organizations that demonstrate cultural relevance, meaningful consumer connection, and a clear commitment to purpose. “We are incredibly proud to be recognized by Fast Company fo.
Business Wire • Dec 12, 2025

Haleon: Fairly Priced Given Limited Growth Drivers
Haleon (HLN) remains a solid consumer goods company, with strong brands like Sensodyne, but growth is incremental and largely price-driven. HLN's recent results show modest organic revenue growth, with volume gains limited and most categories outside oral health underperforming. The company's full-year organic revenue guidance is around 3.5%, but risks from subdued consumer demand and, over the longer term, limited innovation persist.
Seeking Alpha • Dec 8, 2025

First Eagle Overseas Equity ETF Q3 2025 Portfolio Update
Overseas Equity ETF posted a return of 7.27% in the third quarter of 2025. Leading contributors in the First Eagle Overseas Equity ETF this quarter included Samsung Electronics Co Ltd Pfd Non-Voting, Alibaba Group, Barrick Mining, Newmont and Prosus N.V. Class N. The leading detractors in the quarter were Shimano, FUCHS SE Pref Registered Shs, SMC Corporation, Haleon and Philip Morris.
Seeking Alpha • Nov 26, 2025

Haleon plc (HLN) Q3 2025 Sales Call Transcript
Haleon plc ( HLN ) Q3 2025 Sales Call October 30, 2025 5:00 AM EDT Company Participants Joanne Russell - Head of Investor Relations Dawn Allen - CFO & Director Conference Call Participants Guillaume Gerard Delmas - UBS Investment Bank, Research Division Olivier Nicolai David Hayes - Jefferies LLC, Research Division Jeremy Fialko - HSBC Global Investment Research Celine Pannuti - JPMorgan Chase & Co, Research Division Karel Zoete - Kepler Cheuvreux, Research Division Mikheil Omanadze - BNP Paribas Exane, Research Division Tom Sykes - Deutsche Bank AG, Research Division Warren Ackerman - Barclays Bank PLC, Research Division Edward Lewis - Rothschild & Co Redburn, Research Division Presentation Operator Good morning. Thank you for attending today's Haleon 2025 Quarter 3 Trading Statement.
Seeking Alpha • Oct 30, 2025

UK's Haleon posts third-quarter organic revenue marginally above estimates
British consumer healthcare group Haleon reported third-quarter organic revenue growth marginally above market estimates on Thursday, helped by strong demand for its oral health products.
Reuters • Oct 30, 2025

Haleon outlook held steady as organic growth improves in third quarter
Haleon PLC (LSE:HLN, NYSE:HLN) delivered a slight improvement in organic revenue growth of 3.4% in the third quarter and maintained its full-year guidance. The maker of Sensodyne, Panadol and Centrum saw top-line expansion pick up from 3.0% in the second quarter.
Proactive Investors • Oct 30, 2025

Haleon not out of the woods yet, with analysts saying questions still remain
Haleon PLC's (LSE:HLN, NYSE:HLN) third-quarter numbers were in line with expectations and the outlook was maintained, but analysts at Barclays flagged that the toothpaste, painkiller and vitamin maker is not yet out of the woods. Organic sales growth (OSG) of 3.4% for the quarter was in line with the average analyst forecast, helped by better volumes, though the Oral Health arm saw growth short of the City consensus.
Proactive Investors • Oct 30, 2025

Harding Loevner International Equity ADR Q3 2025 Portfolio Update
The International Equity ADR composite rose 3.0% gross of fees in the second quarter, behind the 7.0% gain of the MSCI ACWI ex US Index. In Communication Services, Tencent delivered a second consecutive quarter of double-digit revenue and profit growth. Japan was the largest detractor, with Chugai and Sysmex weighing on results.
Seeking Alpha • Oct 30, 2025

FTSE 100 Index shares to watch: HSBC, Standard Chartered, Haleon, GSK
The FTSE 100 Index rose for four consecutive days and reached its all-time high of £9,578 as traders reacted to key earnings and macro data. It has jumped by over 27% from its lowest level this year.
Invezz • Oct 24, 2025

Are Haleon's headaches set to ease? Here's one leading bank's take
Haleon PLC's (LSE:HLN, NYSE:HLN) management could be forgiven for feeling like pharmacists rearranging the medicine cabinet while the queue outside keeps growing. Barclays, in a detailed preview ahead of the company's third-quarter results, says the consumer health group's biggest headache remains its US inventory build-up, a problem Haleon is determined to “clean up” before year-end.
Proactive Investors • Oct 9, 2025

¹ Disclosures

Open an M1 investment account to buy and sell Haleon plc American Depositary Shares (Each representing two) commission-free¹. Build wealth for the long term using automated trading and transfers.